Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP9801 Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors
NCT03954067Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2019
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP9801 in solid tumor (advanced stage) and metastatic solid tumors (8 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities at 28 days, Safety and tolerability assessed by Adverse Events at 12 months and 3 more. Started Sep 2019; status: completed.
02
Drugs
ASP9801
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT03954067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954067.